Clinical observations of the effect of antidiuretic hormone on nocturia in elderly men

Ho, Dong-Ru; Lin, Wei‐Yu; Wu, Chien-Hsing; Shee, Jia-Jen; Huang, Yun‐Ching; Cheng, Chen-Li

doi:10.1111/j.1464-410x.2005.05829.x

Cited by 4 publications

(2 citation statements)

References 24 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A 43% significant reduction in nocturia was reported after using desmopressin alone ( P < 0.001) [11] . The more severe the nocturia was, the more effective the results with desmopressin, with a 0.756 correlation coefficient between the number of nocturnal voids and the reduction in nocturia after desmopressin treatment.…”

Section: Resultsmentioning

confidence: 95%

Oral desmopressin in nocturia with benign prostatic hyperplasia: A systematic review of the literature

Taha

Aboumarzouk

Shokeir

2018

Arab Journal of Urology

View full text Add to dashboard Cite

ObjectiveTo evaluate the effect of oral desmopressin in patients with nocturia associated with benign prostatic hyperplasia (BPH).Patients and methodsWith a rise of the use of oral desmopressin in the treatment of nocturia in patients with BPH, a systematic review was performed according to the Cochrane systematic reviews guidelines and in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist.ResultsThe literature search yielded 18 studies. The studies were published between 1980 and 2017, and included 3072 patients. Eligible patients were men aged ≥50 years with lower urinary tract symptoms (LUTS) and persistent nocturia. There was a significant 43% reduction in nocturia after using desmopressin alone. Combined α-blockers and desmopressin lead to a decrease in the frequency of night voids by 64.3% compared to 44.6% when using α-blockers only. The first sleep period, significantly increased from 82.1 to 160.0 min and from 83.2 to 123.8 min when using desmopressin + α-blocker and α-blocker only, respectively. The desmopressin dose ranged from the lowest dose (0.05 mg) to the optimum dose (0.4 mg) at bed time. The incidence of hyponatraemia associated with desmopressin use was 4.4–5.7%.ConclusionLow-dose oral desmopressin therapy alone is an effective treatment for nocturia associated with LUTS in patients with BPH. Oral desmopressin combined with α-blockers is well tolerated and beneficial for improving the International Prostate Symptom Score and nocturnal symptoms. All patients should be educated about the mechanism of desmopressin action to avoid treatment discontinuation due to adverse events.

show abstract

Section: Resultsmentioning

confidence: 95%

Oral desmopressin in nocturia with benign prostatic hyperplasia: A systematic review of the literature

Taha

Aboumarzouk

Shokeir

2018

Arab Journal of Urology

View full text Add to dashboard Cite

show abstract

“…Researches for desmopressin response in nocturia without NP are also scarce and debatable. Ho et al had reported a short‐term and small patient population which demonstrated desmopressin to be an effective alternative in nocturia without NP refractory to antimuscarinics . Our report with more study population revealed that desmopressin was statistically effective in reducing nocturnal voids in both groups in a longer treatment period (22.28 ± 13.32 months in non‐NP, 23.95 ± 14.80 months in NP).…”

Section: Discussionmentioning

confidence: 99%

Comparison of nocturia response to desmopressin treatment in elderly men with and without nocturnal polyuria in real-life practice

et al. 2016

View full text Add to dashboard Cite

Objectives: To evaluate the safety and efficacy of low-dose desmopressin in elderly men with and without nocturnal polyuria (NP) in real-life practice. Methods: Patients with lower urinary tract symptoms (LUTS)/ benign prostate hyperplasia (BPH) who were≧ 65 years old with refractory nocturia were enrolled in this study. We retrospectively analysed elderly men treated with adding desmopressin to current medications for nocturia according to category of the baseline nocturnal urine volume. The 48-h frequency volume chart (FVC), International Prostate Symptom Score (IPSS) and quality of life (QoL) were initially assessed and reevaluated 12 weeks later. Serum sodium level was checked 1 week, 4 weeks, and 12 weeks after initiation of desmopressin therapy or suspected hyponatremia event. The mean change in numbers of nocturnal voids was evaluated for efficacy of treatment. Results: A total of 136 patients were included with 55 in non-NP group and 81 in NP group. Hypertension was more common in NP group in regard of comorbidities. During treatment period, there were significant reductions of nocturnal voids from 4.22 AE 1.38 to 2.31 AE 0.98 (p < 0.001) in non-NP group and from 4.52 AE 1.23 to 2.07 AE 0.89 (p < 0.001) in NP group. The reduction in nocturnal voids was more significant in NP group (2.44 AE 1.15 vs. 1.91 AE 1.48, p = 0.003). The mean decrease in serum sodium levels were 3.89 AE 1.22 mmol/l (p < 0.001) in non-NP group and 4.69 AE 3.5 mmol/l (p < 0.001) in NP group at the extreme value. Conclusions: Long-term treatment with low-dose desmopressin is safe and effective for nocturia with or without NP in elderly patients with LUTS/BPH during real-life practice. Patients should be well informed about the disease and are closely followed. What's known• Nocturia is a common reason for interrupted sleep in elderly adults. As patients continue to grow, the complaint of nocturia will become more common and our patients will continue to demand effective and safe therapies to get them through the night.• Nocturnal polyuria (NP) is a subclassification of nocturia characterised by nocturnal urine volume that is over 33% of the 24-h voided volume.• Desmopressin has level 1 evidence and grade A recommendation for the treatment of nocturia because of NP. Randomised, placebo-controlled studies in adults with nocturia because of NP showed that desmopressin can significantly reduce the number of nocturnal voids, decreases the ratio of night/24-h urine volume. What's new• This study revealed that noctutria continued to bother elderly men with lower urinary tract symptoms suggestive of benign prostate hyperplasia despite of stereotyped medical therapy. Adding on low-dose oral desmopressin in real-life practice was shown to be safe and effective for patients over 65 years with nocturia. It also demonstrated desmopressin reduced nocturnal void, IPSS total score and quality of life index not only in NP patients but also in non-NP group in elderly men with comorbidities in reallife practice.

show abstract

Use of desmopressin and concomitant use of potentially interacting drugs in elderly patients in Sweden

Ljung

2008

Eur J Clin Pharmacol

View full text Add to dashboard Cite

The use of desmopressin in the elderly after the new approval in 2002 showed a similar prescription pattern to any newly introduced drug or after a changed indication. A large part of the elderly on desmopressin also receives other drugs that are potentially harmful in combination with desmopressin. Increased awareness of potentially interacting concomitant medication can improve medication safety in this fragile group.

show abstract

Clinical observations of the effect of antidiuretic hormone on nocturia in elderly men

Cited by 4 publications

References 24 publications

Oral desmopressin in nocturia with benign prostatic hyperplasia: A systematic review of the literature

Oral desmopressin in nocturia with benign prostatic hyperplasia: A systematic review of the literature

Comparison of nocturia response to desmopressin treatment in elderly men with and without nocturnal polyuria in real-life practice

Use of desmopressin and concomitant use of potentially interacting drugs in elderly patients in Sweden

Contact Info

Product

Resources

About